Allogeneic transplant experiences in patients with PTCL including a significant proportion of PTCL-NOS patients
| Reference . | No. of patients . | Conditioning, % . | NRM, % . | CR, % . | PFS, % . | OS, % . | PTCL-NOS . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| N (%) . | CR, % . | PFS, % . | OS, % . | |||||||
| 76 | 77 | MA: 74 | 34 (5 y) | 79 | 53 (5 y)* | 57 (5 y) | 27 (35) | 81 | 58 (5 y)* | 63 (5 y) |
| RIC: 26 | ||||||||||
| 77 | 52 | MA: 60 | 27 (3 y) | NA | 30 (3 y) | 41 (3 y) | 20 (38) | NR | NR | NR |
| RIC: 40 | ||||||||||
| 78 | 52 | RIC: 100 | 12 (5 y) | NA | 40 (5 y) | 50 (5 y) | 23 (44) | NR | NR | NR |
| 79 | 126 | MA: 59 | 34 (3 y) | NA | 37 (3 y) | 46 (3 y) | 63 (50) | NR | 33 (3 y) | 42 (3 y) |
| RIC: 36 | ||||||||||
| UNKN: 5 | ||||||||||
| Reference . | No. of patients . | Conditioning, % . | NRM, % . | CR, % . | PFS, % . | OS, % . | PTCL-NOS . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| N (%) . | CR, % . | PFS, % . | OS, % . | |||||||
| 76 | 77 | MA: 74 | 34 (5 y) | 79 | 53 (5 y)* | 57 (5 y) | 27 (35) | 81 | 58 (5 y)* | 63 (5 y) |
| RIC: 26 | ||||||||||
| 77 | 52 | MA: 60 | 27 (3 y) | NA | 30 (3 y) | 41 (3 y) | 20 (38) | NR | NR | NR |
| RIC: 40 | ||||||||||
| 78 | 52 | RIC: 100 | 12 (5 y) | NA | 40 (5 y) | 50 (5 y) | 23 (44) | NR | NR | NR |
| 79 | 126 | MA: 59 | 34 (3 y) | NA | 37 (3 y) | 46 (3 y) | 63 (50) | NR | 33 (3 y) | 42 (3 y) |
| RIC: 36 | ||||||||||
| UNKN: 5 | ||||||||||
MA, myeloablative; NR, not reported; NRM, nonrelapse mortality; RIC, reduced intensity conditioning; UNKN, unknown.
Indicates EFS.